Serum nitric oxide and malondialdehyde in a hypertensive population in Sokoto, Nigeria
DOI:
https://doi.org/10.18203/2320-6012.ijrms20184885Keywords:
Hypertension, Malondialdehyde, Nitric oxideAbstract
Background: Hypertension is recognized as most common cardiovascular disorder and a leading cause of morbidity and mortality worldwide. Endothelial dysfunction, which is associated with impaired nitric oxide is an important risk factor for both hypertension and cardiovascular diseases. There is abnormal lipid peroxidation which suggested that oxidative stress is important in the pathogenesis of hypertension. This study assessed serum levels of nitric oxide and malondialdehyde in hypertensive population in Sokoto-Nigeria.
Methods: A total of 474 subjects who are within the age range of 25 to 76 years, including 316 hypertensive patients and 158 age- and sex- matched normotensive subjects were included in this study. Clinical and anthropometric parameters, nitric oxide and malondialdehyde were measured using standard techniques.
Results: The result indicated that, mean systolic blood pressure (SBP) was significantly (p˂0.001) higher in hypertensive patients (166.00±1.39mmHg) than controls (124.97±0.95 mmHg) similarly the mean BMI was significantly (p˂0.001) higher in hypertensive patients (27.13±0.31 Kg/m2) than controls (23.54±0.12Kg/m2). Mean serum malondialdehyde (MDA) was significantly (p˂0.001) higher in hypertensive patients (3.62±0.07µmol/L) as compared to controls (1.97±0.03µmol/L), while serum nitric oxide (NO) was significantly (p=0.009) lower among hypertensive patients (7.12±0.14µmol/L) than controls (15.26±0.15µmol/L).
Conclusions: Hypertension is a complex disorder that is strongly associated with other risk factors for cardiovascular disease. The aetiology of the association between impaired NO bioactivity, increase MDA and hypertension has not been fully elucidated. Further clarification of the role of impaired NO bioactivity and increased MDA level in hypertension could have important implications for the management of hypertension.
References
Kearney PM, Whelton M, Reynolds K, Jiang H. Worldwide prevalence of hypertension: a systemic review. J Hypertens 2004; 22: 11-9.
Goyal R, Sarwate N. A correlative study of hypertension with lipid profile. Int J Resear Appl Natur Soc Sci. 2014;2(2):143-50.
Richard C, Charles R, Susan A, Daniel M, Babatunde O, Solomon K, et al. The prevalence of hypertension in seven populations of West African origin. Am J Public Health. 1997;87(2):160-68.
Osuji CU, Omejua EG, Onwubuya EI, Ahaneku GI. Serum lipid profile of newly diagnosed hypertensive patients. Int J Hypertens. 2012;2012:7.
Isezuo SA, Okebukola PA. Available at: http://peterokebukola.com/dop/components/com_rsform/uploads/CV_Isezuo-Simeon-Alabi_curriculum-vitae-recent-update.docx.
Brunner H, Cockcroft JR, Deanfield J. On behalf of the Working Group on Endothelins and the Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-46.
Joannides R, Richard V, Haefeli W. Role of basal and stimulated release of nitric oxide in the regulation of radial artery calibre in humans. Hypertens. 1995;26:327-31.
McEniery CM, Schmitt M, Qasem A. Nebivolol increases arterial distensibility in vivo. Hypertens. 2004;44:305-10.
Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atheroscler. 2002;165:191-99.
Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-44.
Lykkesfeldt J, Viscovich M, Poulsen HE. Plasma malondialdehyde is induced by smoking: A study with balanced antioxidant profiles. Br J Nutri. 2004;92:203-06.
Marbut MM, Majeed BM, Rahim SM, Yuusif MN. (2009). Estimation of malondialdehyde as oxidative factor and glutathione as early detectors of hypertensive pregnant women. Tikrit Medic J. 2009;15(2):63-9.
Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993;57(2):715-25.
Schmidt HH. Griess method for nitric oxide assay. Biochemica. 1995;2:22-3.
Shah JK, Walker's AM. Quantitative determination of MDA. Biochemical Biophysics. Anti-counterferfeition Trade Agreement. 1989;11:207-11.
Mathias H, Andreas F, Thomas FL. Nitric oxide in hypertension. J Clin Hypertens. 2006;8(12):17-28.
Armas-padilla MC, Hernande AMJ, Sosa CB, Cammarata R, Pacheco B, Guerrero CAR, et al. Nitric oxide and malondialdehyde in human hypertension. Am J Ther. 2007;2:172-76.
Kanwar G, Jain N, Kirad S, Yadav M, Rathore SP. A study of serum lipid profile in hypertensive patients of Hadoti Region. Int J Res Appl Natur Soci Sci. 2014;2(8):53-60.
Ischiropoulos H, Al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Letters. 1995;364:279-82.
Ito A, Tsao PS, Adimoolam S. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Cir. 1999;99:3092-5.
Wali U, Binji AA, Ahmad K, Usman A. Lipid peroxidation and lipid profile in hypertensive patients in Sokoto, Nigeria. Niger J Bas Appl Sci. 2012;20(3):199-2004.
Vijaya BM, Prashakara RP, Balu MK. Correlative association of interleukin-6 with malondialdehyde in prehypertensive and hypertensive subjects. J Dent Medic Sci. 2015;14(7):53-7.
Crowley SD. The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension. Antio Red Sign. 2014;20(1):102-20.
Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery. 2011;10(6):453-71.
